Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...
MPR3d
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Pharmabiz8d
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...
Arvinas price target lowered to $20 from $82 at BMO Capital
BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
Seeking Alpha8d
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
On Tuesday, based on data from those with estrogen receptor 1 (ESR1m) mutations, the duo said that the protein degrader reached the primary endpoint in their Phase 3 VERITAC-2 trial designed to ...
Business Insider9d
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival ...